Get Ready!

Rosacea treatment and triggers info is on the way.

For Your Rosacea Patients with Inflammatory Lesions

Time to surface

Prescribe the topical that helps them get clearer faster and longer 1, 2, a

Explore the Proposed Dual MOA of Ivermectin3-6
See the Superior Efficacy of Metrocream (Metronidazole) Topical Cream, 0.75%1,2
Learn about the Highly Tolerable Safety Profile1,2
Not an actual patient
Explore the Proposed Dual MOA of Ivermectin3-6
See the Superior Efficacy of Metrocream (Metronidazole) Topical Cream, 0.75%1,2
Learn about the Highly Tolerable Safety Profile1,2

aA phase 3, investigator-blinded, multicenter, randomized, parallel-group study comparing the efficacy and safety of Soolantra® (ivermectin) Cream, 1% once daily with MetroCream® (metronidazole) Topical Cream, 0.75% twice daily in 962 subjects aged 18 years and older with moderate to severe papulopustular rosacea (Investigator’s Global Assessment [IGA] score of 3 or 4) over a 16-week treatment period (Part A). A total of 757 successfully treated subjects, rated clear or almost clear (IGA score of 0 or 1), continued to the 36-week extension evaluating relapse after a treatment-free period (Part B).1,2

In Part B, subjects were followed every 4 weeks for up to 36 additional weeks (Weeks 16-52). If relapse (defined as IGA score of ≥2 [mild, moderate, or severe]) occurred, subjects were re-treated with the same treatment they had received during the initial 16-week study (Part A). Re-treatment was stopped when subject(s) achieved an IGA of ≤1 (clear or almost clear), with a maximum duration of re-treatment of 16 consecutive weeks to mimic the Part A treatment duration. Several re-treatment periods were permitted.2